Alzenau, January 2020–The new family member of the ST-Line by SIGNUS is called JASPIS® ST which recently received CE-approval. The cervical cage originates from the RABEA design, which received the world’s first CE-approval for a plane-parallel fusion cage in 1996. ST stands for Structural Titanium – an additive production process.
The titanium grid structure imitates the architecture of natural cancellous bone to optimise inter-corporeal fusion. The open design of the implant permits the cage to be packed with natural or synthetic bone graft substitute such as KAINOS® Inject, creating the optimal foundation for osseointegration. The roughness of the implant in addition with SIGNUS proven toothed endplate design secures anchorage in the bone owing to high primary stability.
The large surface area of JASPIS® ST maximises the area of contact to the vertebral body and reduces the risk of subsidence. Restoration of the intervertebral space can be guaranteed by a large selection of implants that at the same time offer a high degree of intraoperative flexibility. In addition to 0° cage JASPIS® ST is also available in an 8° lordosis angle to restore sagittal balance. All implants are in individual sterile packaging for immediate use. JASPIS® ST is implanted in the C3 – TH1 by familiar Smith-Robinson surgical technique.
SIGNUS – the Sign for Spine: Passionate! Dynamic! Worldwide!
Innovative high-end implants made in Germany: For more than 25 years, SIGNUS has been the experienced specialist for comprehensive solutions in the surgical spine care sector.Founded in 1994 in Germany’s Lower Franconian city of Alzenau by Susanne and Uwe Siedler, our family-owned company currently has staff of approx. 80 at sites in Germany and Australia. SIGNUS offers the comprehensive product range of cervical spine to SIG sacroiliac joints, which are predominately manufactured at the nearby production site of ProCon Medizintechnik. In addition to Europe (CE) and the USA (FDA), we sell our certified implants throughout the world on every continent. Target-oriented further development of the products in connection with the continuous exchange with the users as well as international further education and hospitalisation programs make SIGNUS a reliable global partner.
The entire SIGNUS Portfolio with detailed information and descriptions are available for you online at www.signus.com